LIVIVO - Search results -

Search results

Result 1 - 10 of total 102

Search options

Article: Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain.

Martínez López, Icíar / Gómez Cerezo, Jorge Francisco / Gámez, José M / Egocheaga Cabello, Isabel / Castellanos, Mar / Campuzano Ruiz, Raquel / Barrios, Vivencio / Pallarés-Carratalá, Vicente / Rodríguez, José Manuel / Morant Talamante, Nuria / Parrondo, Javier / Mostaza, José María

Frontiers in cardiovascular medicine

2024 Volume 11, Page(s) 1324537

Abstract: Introduction: Atherosclerotic cardiovascular disease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The risk of suffering future cardiovascular (CV) events ...

Abstract	Introduction: Atherosclerotic cardiovascular disease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The risk of suffering future cardiovascular (CV) events and the consequent resources use is higher in those patients who have already had a previous cardiovascular event. The objective of the study was to determine the average annual cost of patients with a new or recurrent atherosclerotic CV event during the 2 years after the event. Methodology: Retrospective observational study of electronic medical records of patients from the BIG-PAC® database (7 integrated health areas of 7 Autonomous Communities; Results: A total of 26,976 patients with an ASCVD episode were identified during the recruitment period; Out of them, 6,798 had a recurrent event during the follow-up period and 2,414 died. The average costs per patient were €11,171 during the first year and €9,944 during the second year. Discussion: Patients with ASCVD represent a significant economic burden for the health system and for society. Despite the perception that drug costs in the follow-up of chronic patients imply a high percentage of the costs, these accounted for only one tenth of the total amount. Implementing preventive programs and increasing the control of cardiovascular risk factors may have a significant social and health impact by helping to reduce mortality and costs for the Spanish National Health System. The costs derived from pharmacological treatments were obtained from the NHS pricing nomenclator database (https://www.sanidad.gob.es/profesionales/nomenclator.do).
Language	English
Publishing date	2024-02-28
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2024.1324537
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice.

Delgado-Lista, Javier / Mostaza, Jose M / Arrobas-Velilla, Teresa / Blanco-Vaca, Francisco / Masana, Luis / Pedro-Botet, Juan / Perez-Martinez, Pablo / Civeira, Fernando / Cuende-Melero, Jose I / Gomez-Barrado, Jose J / Lahoz, Carlos / Pintó, Xavier / Suarez-Tembra, Manuel / Lopez-Miranda, Jose / Guijarro, Carlos

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis

2024

Abstract: The irruption of lipoprotein(a) (Lp(a)) in the study of cardiovascular risk factors is perhaps, together with the discovery and use of proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor drugs, the greatest novelty in the field for decades. ... ...

Title translation	Consenso sobre lipoproteína (a) de la Sociedad Española de Arteriosclerosis. Revisión bibliográfica y recomendaciones para la práctica clínica.
Abstract	The irruption of lipoprotein(a) (Lp(a)) in the study of cardiovascular risk factors is perhaps, together with the discovery and use of proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor drugs, the greatest novelty in the field for decades. Lp(a) concentration (especially very high levels) has an undeniable association with certain cardiovascular complications, such as atherosclerotic vascular disease (AVD) and aortic stenosis. However, there are several current limitations to both establishing epidemiological associations and specific pharmacological treatment. Firstly, the measurement of Lp(a) is highly dependent on the test used, mainly because of the characteristics of the molecule. Secondly, Lp(a) concentration is more than 80% genetically determined, so that, unlike other cardiovascular risk factors, it cannot be regulated by lifestyle changes. Finally, although there are many promising clinical trials with specific drugs to reduce Lp(a), currently only iPCSK9 (limited for use because of its cost) significantly reduces Lp(a). However, and in line with other scientific societies, the SEA considers that, with the aim of increasing knowledge about the contribution of Lp(a) to cardiovascular risk, it is relevant to produce a document containing the current status of the subject, recommendations for the control of global cardiovascular risk in people with elevated Lp(a) and recommendations on the therapeutic approach to patients with elevated Lp(a).
Language	Spanish
Publishing date	2024-04-09
Publishing country	Spain
Document type	Practice Guideline
ISSN	1578-1879
ISSN (online)	1578-1879
DOI	10.1016/j.arteri.2024.03.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.

Mostaza, José M / Suárez-Fernández, Carmen / Cosín-Sales, Juan / Gómez-Huelgas, Ricardo / Brotons, Carlos / Araujo, Francisco Pestana / Borrayo, Gabriela / Ruiz, Emilio

BMC cardiovascular disorders

2022 Volume 22, Issue 1, Page(s) 560

Abstract: Background: Cardiovascular (CV) polypills are a useful baseline treatment to prevent CV diseases by combining different drug classes in a single pill to simultaneously target more than one risk factor. The aim of the present trial was to determine ... ...

Abstract	Background: Cardiovascular (CV) polypills are a useful baseline treatment to prevent CV diseases by combining different drug classes in a single pill to simultaneously target more than one risk factor. The aim of the present trial was to determine whether the treatment with the CNIC-polypill was at least non-inferior to usual care in terms of low-density lipoprotein cholesterol (LDL-c) and systolic BP (SBP) values in subjects at high or very high risk without a previous CV event. Methods: The VULCANO was an international, multicentre open-label trial involving 492 participants recruited from hospital clinics or primary care centres. Patients were randomised to the CNIC-polypill -containing aspirin, atorvastatin, and ramipril- or usual care. The primary outcome was the comparison of the mean change in LDL-c and SBP values after 16 weeks of treatment between treatment groups. Results: The upper confidence limit of the mean change in LDL-c between treatments was below the prespecified margin (10 mg/dL) and above zero, and non-inferiority and superiority of the CNIC-polypill (p = 0.0001) was reached. There were no significant differences in SBP between groups. However, the upper confidence limit crossed the prespecified non-inferiority margin of 3 mm Hg. Significant differences favoured the CNIC-polypill in reducing total cholesterol (p = 0.0004) and non-high-density lipoprotein cholesterol levels (p = 0.0017). There were no reports of major bleeding episodes. The frequency of non-serious gastrointestinal disorders was more frequent in the CNIC-polypill arm. Conclusion: The switch from conventional treatment to the CNIC-polypill approach was safe and appears a reasonable strategy to control risk factors and prevent CVD. Trial registration This trial was registered in the EU Clinical Trials Register (EudraCT) the 20th February 2017 (register number 2016-004015-13; https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004015-13 ).
Language	English
Publishing date	2022-12-22
Publishing country	England
Document type	Journal Article
ZDB-ID	2059859-2
ISSN	1471-2261 ; 1471-2261
ISSN (online)	1471-2261
ISSN	1471-2261
DOI	10.1186/s12872-022-03013-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Identification and Functional Analysis of

Rodríguez-Jiménez, Carmen / de la Peña, Gema / Sanguino, Javier / Poyatos-Peláez, Sara / Carazo, Ana / Martínez-Hernández, Pedro L / Arrieta, Francisco / Mostaza, José M / Gómez-Coronado, Diego / Rodríguez-Nóvoa, Sonia

International journal of molecular sciences

2023 Volume 24, Issue 8

Abstract: Mutations ... ...

Abstract	Mutations in
MeSH term(s)	Humans ; Proprotein Convertase 9/genetics ; Apolipoproteins B/genetics ; Cholesterol, LDL/genetics ; U937 Cells ; Hyperlipoproteinemia Type II/genetics
Chemical Substances	PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) ; Apolipoproteins B ; Cholesterol, LDL
Language	English
Publishing date	2023-04-21
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms24087635
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Concentración de colesterol-HDL y riesgo de infección por SARS-CoV-2 en personas mayores de 75 años: una cohorte con medio millón de participantes de la Comunidad de Madrid.

Lahoz, Carlos / Salinero-Fort, Miguel A / Cárdenas, Juan / Rodríguez-Artalejo, Fernando / Díaz-Almiron, Mariana / Vich-Pérez, Pilar / San Andrés-Rebollo, F Javier / Vicente, Ignacio / Mostaza, José M

Hipertension y riesgo vascular

2023 Volume 40, Issue 2, Page(s) 75–84

Abstract: Objective: The aim of this study was to analyze the relationship between HDL-cholesterol and the risk of SARS-CoV-2 infection in over 75-year-olds residing in the Community of Madrid.: Methods: Study of a population-based cohort, composed of all ... ...

Title translation	HDL-cholesterol concentration and risk of SARS-CoV-2 infection in people over 75 years of age: a cohort with half a million participants from the Community of Madrid.
Abstract	Objective: The aim of this study was to analyze the relationship between HDL-cholesterol and the risk of SARS-CoV-2 infection in over 75-year-olds residing in the Community of Madrid. Methods: Study of a population-based cohort, composed of all residents in Madrid (Spain) born before January 1, 1945 and alive on December 31, 2019. Demographic, clinical and analytical data were obtained from primary care electronic medical records from January 2015. Confirmed SARS-CoV-2 infection was defined as a positive RT-PCR or antigen test result. Infection data correspond to the period March 1, 2020 through December 31, 2020. Results: Of the 593,342 cohort participants, 501,813 had at least one HDL-cholesterol determination in the past 5 years. Their mean age was 83.4±5.6 years and 62.4% were women. A total of 36,996 (7.4%) had a confirmed SARS-CoV2 infection during 2020. The risk of infection [odds ratio (95% confidence interval)] for SARS-CoV2 according to increasing quintiles of HDL-cholesterol was 1, 0.960 (0.915-1.007), 0.891 (0.848-0.935), 0.865 (0.824-0.909) and 0.833 (0.792-0.876), after adjusting for age, sex, cardiovascular risk factors and comorbidities. Conclusions: There is an inverse and dose-dependent relationship between HDL-cholesterol concentration and the risk of SARS-CoV2 infection in subjects aged over 75 years of age in the Community of Madrid.
MeSH term(s)	Humans ; Female ; Aged ; Aged, 80 and over ; Male ; COVID-19/epidemiology ; SARS-CoV-2 ; Cholesterol, HDL ; RNA, Viral ; Heart Disease Risk Factors
Chemical Substances	Cholesterol, HDL ; RNA, Viral
Language	Spanish
Publishing date	2023-04-28
Publishing country	Spain
Document type	English Abstract ; Practice Guideline
ISSN	1989-4805
ISSN (online)	1989-4805
DOI	10.1016/j.hipert.2022.12.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Consensus document for lipid profile testing and reporting in Spanish clinical laboratories.

Arrobas Velilla, Teresa / Guijarro, Carlos / Campuzano Ruiz, Raquel / Rodríguez Piñero, Manuel / Valderrama Marcos, José Francisco / Botana López, Antonio M / Morais López, Ana / García Donaire, José Antonio / Obaya, Juan Carlos / Castilla Guerra, Luis / Pallares Carratalá, Vicente / Egocheaga Cabello, Isabel / Salgueira Lazo, Mercedes / Castellanos Rodrigo, María Mar / Mostaza Prieto, José María / Gómez Doblas, Juan José / Buño Soto, Antonio

Endocrinologia, diabetes y nutricion

2023 Volume 70, Issue 7, Page(s) 501–510

Abstract: Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a ... ...

Abstract	Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the lipid control goals appropriate to the vascular risk of the patients in the laboratory reports.
MeSH term(s)	Humans ; Laboratories, Clinical ; Consensus ; Cardiovascular Diseases/prevention & control ; Cardiovascular Diseases/etiology ; Lipid Metabolism ; Lipids
Chemical Substances	Lipids
Language	English
Publishing date	2023-06-01
Publishing country	Spain
Document type	Practice Guideline ; Journal Article
ISSN	2530-0180
ISSN (online)	2530-0180
DOI	10.1016/j.endien.2023.05.012
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Functional foods and nutraceuticals in the treatment of hypercholesterolemia: Statement of the Spanish Society of Arteriosclerosis 2023.

Pérez-Martínez, Pablo / Ros, Emilio / Pedro-Botet, Juan / Civeira, Fernando / Pascual, Vicente / Garcés, Carmen / Solá, Rosa / Pérez-Jiménez, Francisco / Mostaza, José M

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis

2023 Volume 35, Issue 5, Page(s) 248–261

Abstract: In the management of hypercholesterolemia, besides advising a healthy, plant-based diet, it may be useful to recommend functional foods or nutraceutical with cholesterol-lowering properties. Given the progressive increase in the number of these products ... ...

Title translation	Alimentos funcionales y nutracéuticos en el tratamiento de la hipercolesterolemia: posicionamiento de la Sociedad Española de Arteriosclerosis 2023.
Abstract	In the management of hypercholesterolemia, besides advising a healthy, plant-based diet, it may be useful to recommend functional foods or nutraceutical with cholesterol-lowering properties. Given the progressive increase in the number of these products and their rising use by the population, the Spanish Society of Arteriosclerosis (SEA) has considered it appropriate to review the available information, select the results of the scientifically more robust studies and take a position on their usefulness, to recommend to health professionals and the general population their potential utility in terms of efficacy and their possible benefits and limitations. The following clinical scenarios have been identified in which these products could be used and will be analyzed in more detail in this document: (1) Hypolipidemic treatment in subjects with statin intolerance. (2) Hypolipidemic treatment «a la carte» in individuals in primary prevention. (3) Long-term cardiovascular prevention in individuals with no indication for lipid-lowering therapy. (4) Patients with optimized lipid-lowering treatment who do not achieve therapeutic objectives.
MeSH term(s)	Humans ; Anticholesteremic Agents/therapeutic use ; Arteriosclerosis/prevention & control ; Cholesterol ; Dietary Supplements ; Functional Food ; Hypercholesterolemia/drug therapy
Chemical Substances	Anticholesteremic Agents ; Cholesterol (97C5T2UQ7J)
Language	Spanish
Publishing date	2023-03-15
Publishing country	Spain
Document type	Practice Guideline ; Journal Article
ISSN	1578-1879
ISSN (online)	1578-1879
DOI	10.1016/j.arteri.2023.02.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?

Velilla, Teresa Arrobas / Guijarro, Carlos / Ruiz, Raquel Campuzano / Piñero, Manuel Rodríguez / Francisco Valderrama Marcos, José / López, Antonio M Botana / López, Ana Morais / Antonio García Donaire, José / Obaya, Juan Carlos / Castilla Guerra, Luis / Carratalá, Vicente Pallares / Cabello, Isabel Egocheaga / Lazo, Mercedes Salgueira / Rodrigo, María Mar Castellanos / María Mostaza Prieto, José / Doblas, Juan José Gómez / Soto, Antonio Buño

Nefrologia

2023 Volume 43, Issue 4, Page(s) 474–483

Abstract	Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the lipid control goals appropriate to the vascular risk of the patients in the laboratory reports.
MeSH term(s)	Humans ; Lipids ; Laboratories, Clinical ; Consensus ; Cardiovascular Diseases/prevention & control
Chemical Substances	Lipids
Language	English
Publishing date	2023-10-08
Publishing country	Spain
Document type	Practice Guideline ; Journal Article
ZDB-ID	2837917-2
ISSN	2013-2514 ; 2013-2514
ISSN (online)	2013-2514
ISSN	2013-2514
DOI	10.1016/j.nefroe.2023.08.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: what parameters should a basic lipid profile include?

Arrobas Velilla, Teresa / Guijarro, Carlos / Ruiz, Raquel Campuzano / Piñero, Manuel Rodríguez / Valderrama Marcos, José Francisco / Pérez Pérez, Antonio / Botana López, Antonio M / López, Ana Morais / García Donaire, José Antonio / Obaya, Juan Carlos / Castilla-Guerra, Luis / Carratalá, Vicente Pallares / Cabello, Isabel Egocheaga / Lazo, Mercedes Salgueira / Castellanos Rodrigo, María Mar / Mostaza Prieto, José María / Gómez Doblas, Juan José / Buño Soto, Antonio

Advances in laboratory medicine

2023 Volume 4, Issue 2, Page(s) 138–156

Abstract	Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the lipid control goals appropriate to the vascular risk of the patients in the laboratory reports.
Language	Spanish
Publishing date	2023-06-05
Publishing country	Germany
Document type	Journal Article
ISSN	2628-491X
ISSN (online)	2628-491X
DOI	10.1515/almed-2023-0047
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Prevalence of atrial fibrillation and associated anticoagulant therapy in the nonagenarian population of the Community of Madrid, Spain.

Lahoz, Carlos / Cardenas, Juan / Salinero-Fort, Miguel Á / Mostaza, José M

Geriatrics & gerontology international

2018 Volume 19, Issue 3, Page(s) 203–207

Abstract: Aims: The objective of the present study was to evaluate the prevalence of atrial fibrillation (AF) in nonagenarians living in the Community of Madrid, their clinical features, the use of anticoagulant therapy and factors associated with its use.: ... ...

Abstract	Aims: The objective of the present study was to evaluate the prevalence of atrial fibrillation (AF) in nonagenarians living in the Community of Madrid, their clinical features, the use of anticoagulant therapy and factors associated with its use. Methods: This was a cross-sectional study of 59 423 individuals aged ≥90 years, living in the Community of Madrid on 31 December 2015. Clinical information was obtained from a database that includes information from electronic medical records collected by 3881 general practitioners in primary care. Results: Some 16.95% of nonagenarians (n = 10 077) were diagnosed with atrial fibrillation. These individuals have a higher prevalence of classic risk factors and established cardiovascular disease, as well as higher comorbidity. Of these, 67.6% received anticoagulant therapy, 27.9% received antiplatelet agents and 7.2% received both treatments simultaneously. Of the participants administered anticoagulation, 11.6% received a direct oral anticoagulant. The use of anticoagulant therapy was associated with a younger age, the presence of heart failure or venous thromboembolism, the absence of hypertension, a higher Barthel Index score, a greater number of prescribed drugs, a higher body mass index and a lower Charlson Comorbidity Index score. Conclusions: Nonagenarians with atrial fibrillation have a high risk of stroke; however, high comorbidity and functional impairment have limited the use of anticoagulant therapy. Geriatr Gerontol Int 2019; 19: 203-207.
MeSH term(s)	Age Factors ; Aged, 80 and over ; Anticoagulants/therapeutic use ; Atrial Fibrillation/complications ; Atrial Fibrillation/epidemiology ; Cross-Sectional Studies ; Female ; Humans ; Male ; Platelet Aggregation Inhibitors/therapeutic use ; Prevalence ; Primary Health Care ; Spain ; Stroke/epidemiology ; Stroke/prevention & control
Chemical Substances	Anticoagulants ; Platelet Aggregation Inhibitors
Language	English
Publishing date	2018-12-18
Publishing country	Japan
Document type	Journal Article
ZDB-ID	2113849-7
ISSN	1447-0594 ; 1444-1586
ISSN (online)	1447-0594
ISSN	1444-1586
DOI	10.1111/ggi.13587
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5801: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito